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Abstract
Background: The prevention and treatment of coronary heart disease (CHD) is complex. A
variety of models have therefore been developed to try and explain past trends and predict future
possibilities. The aim of this systematic review was to evaluate the strengths and limitations of
existing CHD policy models.
Methods: A search strategy was developed, piloted and run in MEDLINE and EMBASE electronic
databases, supplemented by manually searching reference lists of relevant articles and reviews. Two
reviewers independently checked the papers for inclusion and appraisal. All CHD modelling studies
were included which addressed a defined population and reported on one or more key outcomes
(deaths prevented, life years gained, mortality, incidence, prevalence, disability or cost of
treatment).
Results: In total, 75 articles describing 42 models were included; 12 (29%) of the 42 models were
micro-simulation, 8 (19%) cell-based, and 8 (19%) life table analyses, while 14 (33%) used other
modelling methods. Outcomes most commonly reported were cost-effectiveness (36%), numbers
of deaths prevented (33%), life-years gained (23%) or CHD incidence (23%). Among the 42 models,
29 (69%) included one or more risk factors for primary prevention, while 8 (19%) just considered
CHD treatments. Only 5 (12%) were comprehensive, considering both risk factors and treatments.
The six best-developed models are summarised in this paper, all are considered in detail in the
appendices.
Conclusion: Existing CHD policy models vary widely in their depth, breadth, quality, utility and
versatility. Few models have been calibrated against observed data, replicated in different settings
or adequately validated. Before being accepted as a policy aid, any CHD model should provide an
explicit statement of its aims, assumptions, outputs, strengths and limitations.
Background
Improving population health through effective interven-
tions remains a fundamental challenge for policy makers.
Decision-makers at the population and individual levels
each need to choose the 'best intervention' for a specific
health problem. However, limitations on resources, time
and information can make this decision process difficult.
This is particularly true for cardiovascular disease, its
diversity of manifestations and wealth of effective inter-
ventions are potentially complex and confusing. Assessing
the potential population benefit of a health intervention
requires consideration of many elements including dis-
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ease prevalence and population characteristics, effective-
ness and cost [1]. Clinical trials will never provide all the
answers, particularly since their study groups are restricted
with inclusion and exclusion criteria; therefore generalisa-
tion is always an issue [2]. Weinstein has usefully defined
a model as, "a logical mathematical framework that per-
mits the integration of facts and values to produce out-
comes of interest to clinicians and decision makers" or,
alternatively as: "an analytical methodology that accounts
for events over time and across populations based on data
drawn from primary or secondary sources"[3].
Models have been increasingly used in policy making and
resource allocation, because they permit policy makers to
simulate the effects of different scenarios within a popula-
tion[4] and hence examine future policy options.
An appropriate model for coronary heart disease (CHD)
could thus potentially allow users to simultaneously con-
sider all the key issues when evaluating diverse options for
intervention.
A remarkably wide variety of CHD policy models exist.
Some simply consider risk factors alone[5], while others
include selected cardiovascular treatments[1,6,7] second-
ary prevention such as cholesterol lowering treatment[8]
or estimates of general practice workload [9]. However,
model construction and development is complex and dif-
ficult. Thus, few CHD models have attempted a compre-
hensive consideration of all standard treatments and all
major risk factors[10]. Furthermore, the variable quality
and utility of different models may not always be appreci-
ated.
In this paper we have systematically reviewed and evalu-
ated the strengths and limitations of existing CHD policy
models. Critiquing and providing a comprehensive over-
view of all CHD models is a challenging task. Although it
is useful to have a broad summary of the similarities and
differences of models, it is virtually impossible to capture
the complexity and subtlety of a range of models in a sin-
gle paper. However, this paper represents our best efforts,
and will hopefully serve as an overview and introduction
to this complex field. It will also provide sources and
routes to further information on specific models.
Methods
For this systematic review, we defined a CHD policy
model as any mathematical tool that may help to explain
or predict the outcome of CHD interventions: specific
treatments or cardiovascular risk factor changes or the
implementation of a new strategy at a population level.
Search strategy
A search strategy was developed, piloted and run in
MEDLINE and EMBASE electronic databases on 12th May
2003, supplemented by screening reference lists of rele-
vant articles and reviews. Electronic searching within the
databases included 'coronary heart disease or synonyms'
and 'model or synonyms' as key words. Both key words
and MeSH headings were used (Appendix 1) [see Addi-
tional file 1]. The search strategy was validated using ten
key papers already known to the authors; all ten papers
were captured by the search strategy. The search initially
identified 4,531 articles and checking the references iden-
tified a further 17. All the records were imported to 'Refer-
ence Manager'. By checking the titles and abstracts for the
terms 'model', 'coronary heart disease' or 'population', the
number of articles was reduced to 275. Two reviewers
(BU, SC) independently checked the titles and abstracts of
all papers initially identified, and then independently
screened the articles for inclusion and appraisal. Agree-
ment between the two reviewers was good (Kappa = 0.76).
Inclusion and exclusion criteria
Any CHD modelling study was included if it reported on
a key outcome (deaths prevented, life years gained, pre-
vention cost, treatment cost, mortality, prevalence, inci-
dence or disability) in a defined population (community,
region or country). Models were excluded if they simply
described animals, cell lines, clinical series, cohorts or
estimates of individual risk. Decision analytic models
were also not included in this review since they mostly
focused on clinical decision making in individuals, rather
than population benefits.
Figure 1 illustrates the flowchart for the search and review
process. Excluded articles are listed in Appendix 4 [see
Additional file 1]. In total, 75 articles were included for
critical appraisal and 200 articles were excluded.
Data extraction and assessment of model quality
A pre-piloted form was used for data extraction (Appendix
2) [see Additional file 1]. Articles were categorised accord-
ing to the specific models that they described. Each paper
was then critically appraised by two reviewers using
explicit quality criteria. There are no universally accepted
lists of appropriate quality criteria for model papers. How-
ever reviews by Weinstein [11], and Edwards [12], and
recent guidelines from the International Society for Phar-
macoeconomics and Outcomes Research (ISPOR) [3]
have suggested useful quality criteria. Using these sources
[3,11,12], we created, piloted and refined a grading sys-
tem, based on sensitivity, validity and transparency of the
model (Appendix 3) [see Additional file 1].BMC Public Health 2006, 6:213 http://www.biomedcentral.com/1471-2458/6/213
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Quality measures
Papers were evaluated on the basis of whether a sensitivity
analysis was carried out, the validity was checked, data
quality was reported, illustrative examples were provided,
assumptions stated, if model was potentially available to
the reader (transparency), and if potential limitations
such as assumptions, confounding, lag times and compet-
ing causes were specified or discussed. The model evalua-
tion was based on authors' reporting on that specific item
in the related articles. A model was considered as compre-
hensive if it included multiple coronary heart disease cat-
egories, and a range of treatments and major risk factors.
Limitations of the review
Our search was limited to English language articles or
abstracts. Publication bias can be an issue since our search
was mostly based on electronic search of biomedical data-
bases. The grey literature was not formally searched; how-
ever, we contacted key people who were working in this
field.
Results
From 4,531 initial papers, a total of 75 articles describing
42 different CHD policy models were finally included
(Figure 1). Each was originally used to address one or
more specific health policy questions and all were based
on large populations. Due to space restrictions, we present
here details of the six principal CHD policy models, which
generated more than one publication that selected for this
review (Table 1). Critical appraisals of all 75 papers and
all 42 models (including 6 models presented here) are
provided in Appendix 3 [see Additional file 1].
Transparency and limitations of the models
The majority of the models (36, 86%) explicitly stated
their key assumptions. However, illustrations or examples
of estimations were provided in only 14 (33%). Working
versions of the models were potentially available in just 4
(10%).
Barely one fifth of the models reported on limitations of
their methodology such as competing causes (8, 19%), lag
times (7, 17%) or confounding (8, 19%).
Papers excluded from the systematic review
Papers excluded are listed alphabetically in Appendix 4
[see Additional file 1] with reasons for exclusion. The
commonest reasons for exclusion were that the paper was
not a modelling study, that it did not report on CHD out-
comes, or that it was only a review.
Methodology and structure of the six principal CHD policy 
models
The details on model methodology used in modelling
papers included in this review can be seen in the Appen-
dices [see Additional file 1].
The methodology used in models varied widely. The Cor-
onary Heart Disease Policy (CHDP) Model is a state-tran-
sition, cell based model developed in the1980s [13]. It
was initially used to examine trends in CHD mortality
[14,15] and expected gains in life expectancy from risk fac-
tor modifications [16]. This model was also used to eval-
uate the cost-effectiveness of specific medical
interventions for primary and secondary prevention of
CHD [7,17-19] and health promotion activities [20].
The model was based on the 1980 US population and
mortality statistics. It consists of three sub-models:
- A demographical/epidemiological model, which represents
the disease-free population aged 35–84 years, stratified by
sex, age group and cardiovascular risk factors. This model
includes risk factors as categorical variables, therefore over
5,000 cells are required in total. It then uses a logistic risk
Flowchart of search strategy for CHD policy models Figure 1
Flowchart of search strategy for CHD policy models.
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Table 1: Summary of the six principal CHD policy models
Name of the 
model (Author)
Type of model Model setting & 
Study 
population(s)
Risk factors 
included
Disease groups & 
treatments 
included
Outcomes Sensitivity 
analysis
Validation Strengths and 
limitations
CHD Policy 
Model (Weinstein 
and Goldman)
State transition 
Markov Model
USA, Men and 
Women aged 35–84
Smoking, total 
cholesterol, DBP 
and weight to 
estimate CHD risk 
using Framingham 
Equations
Angina, AMI, sudden 
death, post MI, 
CABG, PTCA
Specific treatments 
considered in 
different studies eg 
statins, aspirin, beta-
blockers etc
Number of deaths 
prevented, LYG, 
CHD incidence 
(number of arrests, 
angina, AMI), CHD 
prevalence, CHD 
mortality, cost per 
life year
In the initial model 
none. Subsequently 
papers reported one 
way sensitivity 
analysis
Model was 
calibrated using 
1986 mortality data.
Validity: Model 
estimates were 
compared with 1990 
observed-92–98% fit 
reported.
First policy model 
rather basic.
Steadily refined since 
then.
Many papers in high 
impact journals
PREVENT 
(Gunning-
Scheppers)
Cell based Netherlands; 
Denmark, England
Depending on the 
purpose aged <65
Smoking, 
cholesterol, 
hypertension, 
obesity, physical 
activity, alcohol
None Number of deaths 
prevented, life years 
gained
One way, different 
scenarios
Not checked Mainly a primary 
prevention model. 
Developed and 
adopted in several 
different populations.
CHD Life 
Expectancy 
Model (Grover et 
al)
Life table 
analysis-Markov 
model from 1998 
onwards
Canada, Adult men 
and women, age 
group not clear
Smoking, total 
cholesterol, DBP, 
glucose intolerance, 
age
Did not consider 
CHD disease 
categories but 
treatments can be 
considered for 
primary prevention
Years of life saved, 
cost per life year 
saved, years of life 
without CHD 
symptoms
One-way Calibrated This model uses 
hypothetical cohorts of 
participants. In most of 
the papers, time and 
the specific population 
are not clear.
CHD Policy 
Analysis 
(Sanderson and 
Davies)
Micro simulation England and Wales,
Up to 85 years. Men 
and women
Smoking, 
cholesterol, systolic 
blood pressure
Angina (stable and 
unstable), AMI, 
postMI, CABG, 
PTCA None
Deaths prevented, 
morbidity 
prevented, CHD & 
non-cardiac deaths, 
unstable angina 
admissions, 
investigations, 
angiograms, PTCA, 
CABG
No validation 
reported
Separate risk factor and 
treatment components. 
Future model may 
include secondary 
prevention treatments. 
No sensitivity analyses 
yet. Model fit appears 
better for men than 
women.
IMPACT 
(Capewell, 
Critchley and 
Unal)
Spread-sheet Scotland, England & 
Wales, New 
Zealand.
Initially men and 
women aged 45–84. 
IMPACT Model for 
England and Wales 
includes 25–84
Initially smoking, 
cholesterol, blood 
pressure – then also 
obesity, diabetes 
and physical activity 
and deprivation
This model is 
comprehensive and 
considers all 
principal CHD 
categories and over 
20 specific CHD 
treatments
Deaths prevented 
or postponed, life 
years gained.
Multi way sensitivity 
analysis using 
Analysis of extremes 
method.
Estimated falls in 
CHD mortality 
were compared 
with observed falls 
over specific time 
period stratified by 
age and sex.
Considers all major 
effective treatments 
available for CHD and 
all major risk factors.
Data quality adequate, 
used trial and meta-
analyses: National 
population statistics 
and results from 
representative studies
Global Burden of 
Disease (Murray 
and Lopez)
Population 
attributable risk 
method
World divided into 
eight geographic 
regions
M-F all ages
Malnutrition, poor 
water, unsafe sex, 
alcohol, tobacco 
occupation, 
hypertension, 
physical activity, 
illicit drugs, and air 
pollution
None Disability adjusted 
life years (DALYs)
Multi-way sensitivity 
analysis-discounting 
and age weighting
None A comprehensive and 
global model for WHO 
strategies. Well 
documented and 
described. CHD is 
included, and modelled 
as caused by tobacco 
use, hypertension and 
physical inactivity, and 
reduced by alcohol.
Data quality: Extremely 
variable depending on 
the regionBMC Public Health 2006, 6:213 http://www.biomedcentral.com/1471-2458/6/213
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function based on the Framingham equation to estimate
the annual incidence rates of CHD events for each cohort.
- A bridge model, which covers subjects for the first 30 days
after they develop coronary disease. Using CHD incidence
data from Minnesota, the model initially determines
whether the first event is angina, myocardial infarction or
cardiac arrest[13].
- A disease history model, which includes the survivors after
the first 30 days, places them in 12 CHD states by age and
sex, and then follows them through treatment pathways.
This model allows the user to simulate the effects of an
intervention (either risk factor modification, or therapy)
by changing case fatality rates and observing the effect on
mortality, morbidity and costs for up to 30 years.
The CHD Policy Analysis Model, comprised two distinct
parts. The primary prevention component of the model
developed by the London School of Hygiene and Tropical
Medicine aims to simulate the impact of different primary
prevention strategies on benefits and costs [21]. The treat-
ment component of the model developed in the Universi-
ties of Southampton and Birmingham[21,22] evaluates
the impact of different treatments given to two different
groups of CHD patients, stable angina or acute myocar-
dial infarction[21].
PREVENT was a cell based model developed by Gunning-
Schepers in the Netherlands during the 1980s [23]. It has
been used to estimate the health benefits of changes in
population risk factor prevalence by comparing i) contin-
uation of existing trends with ii) alteration of the propor-
tions of the population with given risk factor levels. The
model allowed one risk factor to be associated with more
than one disease and one disease to be associated with
more than one risk factor. Demographic evolution was
also taken into account in simulations[23].
The Cardiovascular Life Expectancy Model was initially
developed by Grover et al in 1992 in Canada to examine
the cost-effectiveness of different treatment options for
CHD[5]. From 1998 onwards the model was also
described as a Markov model. The model includes pri-
mary and secondary prevention parts. The primary CHD
part calculates the annual probability of dying (from CHD
or other causes) and the annual risk of CHD events (with
or without intervention) for a person without sympto-
matic CHD at entry to the model. The annual risk of
developing specific CHD endpoints is based on data from
the Framingham Heart Study.
After developing CHD, a person then moves to the second-
ary CHD model. This part calculates the risk of dying dur-
ing the 12 months following a non-fatal myocardial
infarction. The risk estimations are based on the Framing-
ham logistic equations for primary events after adjust-
ment for the presence of CHD[5].
The difference between the predicted annual cumulative
mortality with and without the intervention over the
remaining total life expectancy then represents the total
years of life saved after that intervention.
The IMPACT CHD mortality model is a cell-based model
originally developed by Capewell and colleagues in
1996[6]. Using a MS EXCEL spreadsheet, this model com-
bines data from many sources on patient numbers, treat-
ment uptake, treatment effectiveness, risk factor trends
and consequent mortality effects. The deaths prevented or
postponed (DPPs) over a specified time period are then
estimated. The model can therefore be used to estimate
the proportion of a mortality decline (or increase) over a
certain time span that might be attributed to specific treat-
ments or risk factor changes. It can also examine the con-
sequences of increasing treatments provided, or reducing
risk factor levels. Other outputs include life years gained
and cost-effectiveness of specific interventions (Appendix
3) [see Additional file 1].
The Global Burden of Disease (GBD) model was devel-
oped at WHO by Lopez and Murray. It is an example of a
model, which uses population attributable risk percentage
(PAR %) estimations. The model can calculate the attrib-
utable burden of disease for a specific risk factor, popula-
tion and time, defined as the difference between currently
observed burden and the burden that would be observed
if past levels of exposure had been equal to the lowest rel-
ative risk [24,25]).
The GBD Model has five components: causes of death,
descriptive epidemiology of disabling sequelae, burden
attributed to selected risk factors, projections of burden
for the future and sensitivity analyses. Cause of death data
are obtained from vital registrations or other sources. Data
on 107 disorders and selected disabling sequel were inves-
tigated regarding average age of onset, duration, incidence
and prevalence. Burden of disease and injury attributable
to ten major risk factors were then calculated. The model
uses attributable fractions, taken from reviews and meta-
analyses, applied to the population of a region to calculate
the burden of disease attributable to these risk factors
[25]. Where data were not available, assumed values were
used. Burden of disease is measured using disability
adjusted life years (DALYs), calculated as the sum of years
lost and years lived with disability [26].BMC Public Health 2006, 6:213 http://www.biomedcentral.com/1471-2458/6/213
Page 6 of 10
(page number not for citation purposes)
Comprehensiveness
The Coronary Heart Disease Policy Model includes major
risk factors such as smoking, total cholesterol, DBP and
relative weight, which are necessary to estimate CHD risk
using Framingham Equations. The model considers most
CHD categories. Individual CHD treatments such as stat-
ins, aspirin, and beta-blockers have also been considered
in different publications[7,17,18].
The PREVENT Model is a primary prevention model and
therefore only considers risk factors: smoking, cholesterol,
hypertension, obesity, physical activity and alcohol use
[27-30].
The Cardiovascular Life Expectancy Model estimates the
annual risk of developing specific CHD endpoints. Ini-
tially based on data published from the Framingham
Heart Study from 1998 onwards the model used data
from the Lipid Research Clinic follow up cohort. It there-
fore includes risk factors of age, sex, diastolic blood pres-
sure, total cholesterol, HDL cholesterol level, left
ventricular hypertrophy, glucose intolerance and smoking
status [31-33]. The only treatment considered was statins.
[31-33]
The CHD Policy Analysis Model has separate primary pre-
vention and CHD treatment parts. The primary preven-
tion component includes risk factors such as age, sex,
systolic blood pressure, total cholesterol, and smok-
ing[21]. The disease events included are stable angina,
unstable angina, myocardial infarction, sudden cardiac
death, stroke death, other cardiovascular death, cancer
death and death from other known and unknown
cause[21]. The CHD Policy Analysis Model originally
aimed to include many treatment categories but the only
publication thus far focuses on angina [31-33].
The IMPACT Model considers a comprehensive range of
risk factors, CHD categories and treatments. For primary
prevention the model includes smoking, cholesterol,
blood pressure[6,34-36], deprivation, obesity, diabetes,
physical activity and also primary prevention with anti-
hypertensive medications and statin therapies [37].
The disease categories and treatments include: AMI: (Car-
diopulmonary resuscitation, thrombolysis, aspirin, angi-
oplasty, beta blockers and ACE inhibitors); Secondary
prevention following MI, and, separately, following
CABG or angioplasty: (aspirin, beta blockers, ACE inhib-
itors, statins, warfarin and rehabilitation); Chronic
angina: (CABG surgery, angioplasty, aspirin, statins);
Unstable angina: (aspirin, heparin, platelet IIB/IIIA
inhibitors and clopidogrel); Heart failure: (ACE inhibi-
tors, beta blockers, spironolactone, aspirin, statins) and
all standard treatments for Hypertension.
The Global Burden of Disease Model includes ten major
risk factors for global disease burden: malnutrition, poor
water quality, unsafe sex, alcohol, occupation, tobacco
use, hypertension, physical inactivity, illicit use of drugs,
and air pollution[25]. CHD is included in the model, and
is modelled as being caused by tobacco use, hypertension
and physical inactivity, and reduced by all levels of alco-
hol consumption.
Model populations
Most of the models were restricted to young and middle-
aged groups, generally 15 to 64 years (Tables 1–7 in
Appendix 3) [see Additional file 1]. However, the CHD
Policy Model, IMPACT and the CHD Policy Analysis
Model considered groups aged up to 84 years. None of the
models specifically considered non-Caucasian popula-
tions.
Model outcomes
The most common outcomes reported were numbers of
deaths prevented, life-years gained, CHD incidence and
cost or cost-effectiveness (Table 1 and Appendix3) [see
Table 2: Suggestions for future papers reporting on CHD policy models
A CHD modelling paper should explicitly report and discuss;
-Aims of the project
-Structure and methods of the model
-Data quality (data availability, how up to date, comprehensive, any gaps in certain population groups or interventions). Reasons for selecting or 
excluding specific data sources
-Methodological limitations
-The assumptions used to address these deficiencies
-Sensitivity analyses (one-way or preferably multi-way)
-Whether the validity of the model was checked (with real observational data or with other models)
-Replication of the model in different populations
-Model results and comparisons with other studies
-Social and economic policy implications of model outcomes
Suggestions for future researchBMC Public Health 2006, 6:213 http://www.biomedcentral.com/1471-2458/6/213
Page 7 of 10
(page number not for citation purposes)
Additional file 1]. Among the six models included in this
paper, CHD Policy Model, PREVENT, IMPACT, Global
Burden of Disease and CHD Policy Analysis have capabil-
ity to predict future trends in disease and other related
outcomes except the Cardiovascular Life Expectancy
Model. This model has been used to assess cost-effective-
ness of interventions rather than predicting or explaining
the trends.
Model quality
Relatively few papers included in this review reported on
quality issues. In a few models, sensitivity analyses were
reported, examining the effect of varying key factor such as
treatment costs or measurement imprecision. However,
the majority were one-way analyses (varying one factor at
a time), rather than the more rigorous multi-way sensitiv-
ity analyses (varying several factors simultaneously)
(Table 1 and Appendix 3) [see Additional file 1].
Assessment of validity was reported in very few models. In
the CHD Health Policy Model, this was done by compar-
ing the CHD deaths estimated by the model with the actual
CHD deaths observed in 1990 [14]. In the IMPACT
Model, validity was likewise checked by comparing the
estimated fall in CHD deaths with the observed fall in spe-
cific age and sex categories[6,37]. In PREVENT, model
validity was checked by comparing model estimates with
another estimation method[38]. In the Cardiovascular
Life Expectancy Model, predictive validity was checked by
comparing the model estimates with events observed in
primary and secondary prevention trials[39,40]. The orig-
inal 1992 Cardiovascular Life Expectancy model was sim-
ilarly validated against the data set from the Lipid
Research Clinic cohort [32].
The CHD Health Policy model was similarly calibrated
using life years estimated from the model compared with
life expectancy from 1980 national statistics [16]. Only
two of the models had been replicated in different popu-
lations (PREVENT[28,41] and IMPACT [6,10,34-
37,42,43]).
Discussion
This is the first comprehensive systematic review of CHD
policy models. Previous reviews were restricted to a partic-
ular type or application [44-46]. The increasingly wide use
of CHD modelling has thus far resulted in few attempts to
evaluate model quality. We therefore aimed to systemati-
cally assess the quality of the modelling methodology
rather than simply comment on the reported results.
A wide variety of CHD policy models have been devel-
oped with over 70 publications now available. CHD mod-
els have become more complex and comprehensive as a
result of improving computer technology and wider
usage[10]. Although, on the surface many of the models
may appear similar, one must remember that they were
often originally designed to address very different policy
questions.
In general, the quality of the models has also improved
over time so that more recent papers tend to explicitly
report assumptions, limitations and sensitivity analyses.
Quality criteria assessing for publications are well
described, especially for randomised controlled stud-
ies[47]. However, there are no widely accepted quality cri-
teria for modelling papers in general nor specifically for
CHD policy models. We therefore first had to develop an
evaluation framework using logical quality criteria includ-
ing sensitivity analyses, validity, and comprehensive
reporting of assumptions and limitations (Appendix 3)
[see Additional file 1]. These criteria explicitly reflect the
main quality components suggested in the recent ISPOR
Guideline [3].
Models can allow a large amount of evidence to be con-
sidered simultaneously, by combining and integrating
into a coherent whole different types of data from control-
led trials, routine surveillance and expert consensus[10].
Models have been extensively used in policy making and
resource allocation, since they permit policy makers to
examine future options, or to simulate the effects of differ-
ent scenarios within a population [4]. However, improved
technology potentially increasingly enables practitioners
and policy-makers to use these models without necessar-
ily understanding the inherent assumptions or data limi-
tations [10].
Models require considerable data input. The data sources
therefore need to be appropriate and credible. However,
the availability of comprehensive high quality data
remains a problem. The data are therefore usually
obtained from a variety of sources including clinical trials,
meta-analyses, surveys, clinical databases and registries,
medical records, audits, routine statistics, official tariff
lists for health care resource use and Delphi panels (to
elicit expert opinion)[48]. Every CHD modelling paper
should therefore explicitly report and critically discuss
data quality, methodological limitations and the assump-
tions used to address these deficiencies. However, few of
the papers reviewed here did so.
Uncertainties about data are a perennial problem in mod-
elling studies. Sensitivity analyses are therefore essential
to quantify the degree of uncertainty. In general, CHD
models have only recently started to report sensitivity
analyses [14,40,49]. The most common approach is
where one or more parameters of an evaluation are varied
across a plausible range[50]; 95% confidence intervals canBMC Public Health 2006, 6:213 http://www.biomedcentral.com/1471-2458/6/213
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easily be included. One-way sensitivity analysis (where
only one parameter is changed at a time while the others
retain their base-case specifications) is obviously less rig-
orous than multiway-sensitivity analysis (where more than
one parameter is changed at the same time). However,
multiway sensitivity analyses remain very uncommon
[6,10,37]. Lately, the use of probabilistic sensitivity anal-
ysis has been suggested alongside with traditional sensi-
tivity analyses. Probabilistic sensitivity analyses offer the
opportunity to make statistical statements about the
impact of parameter uncertainty in models. Although, this
approach has been criticized for its arbitrariness in choos-
ing the statistical distribution it may be used more often
in the future [51]. Probabilistic sensitivity analysis was not
used in any of the reviewed models in this paper.
Implications for policy and practice
Many of the papers included in this systematic review
failed to provide sufficient detail to allow thorough eval-
uation of the model used. This obviously constrained our
systematic review. When assessing the quality of a model,
one should ideally consider the system being modelled,
the model structure, the elements included and excluded,
the probable effects of existing trends in mortality and risk
factors and the model assumptions-both explicit and
implicit[3,4]. The description of the model should be suf-
ficiently detailed so that the model can be replicated
mathematically. Therefore modeling papers should
include some basic information on models listed in Table
2. If the validity of a model cannot be checked, it simply
represents a "black box" rather than a useful tool. More
extensive validation studies thus represent a priority for
future research. Although most of the models have poten-
tial to predict future trends depending on how the model
is populated, the methodological challenges are consider-
able, and there is substantial need for further research and
development.
Finally, although this review focussed on CHD models,
many of the issues are generic. Some findings may there-
fore be cautiously generalisable when modelling other
diseases or interventions.
Conclusion
In conclusion, CHD models offer a potentially valuable
tool for policy development. However, existing models
vary widely in their depth, breadth and quality. Few mod-
els have been calibrated, replicated or validated against
minimum quality criteria. Before being accepted as a pol-
icy aid, any model should explicitly include a statement of
its aims, assumptions, outputs, strengths and limitations.
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